

EMPA-KIDNEY Has Recruited To Target!

To all EMPA-KIDNEY participants,

Thank you for all your time and effort in committing to the ongoing EMPA-KIDNEY trial. On 16th April 2021, we completed randomization of the 6609th participant, so we have reached our intended targets. It has taken a collaborative effort from 235 hospitals worldwide in eight contributing countries and nearly two years to complete recruitment to what is one of the largest trials

ever conducted with people with kidney disease. This is a major achievement that would not have been possible without your commitment and that of the research teams in your area, particularly given all the challenges of the COVID-19 pandemic. Your efforts - to join the trial, continuing to be seen in our follow-up clinics, and taking study tablets - mean that EMPA-KIDNEY is set to provide really important information on the effects of empagliflozin in people with chronic kidney disease.

Plans for 2021 and 2022

We anticipate that the trial will continue all the way through 2021 and into 2022. There is no fixed date in 2022 when the trial will end as we are continuously monitoring the trial data, and will stop the trial when we have accumulated enough information to provide conclusive results. We will let you know when we reach this point, and will also let you know the results as soon as we can. Other news will continue to be posted on:

www.empakidney.org

If you have had telephone follow-up calls, please don't be surprised if your local study team ask you to come back to catch

up on the missed blood sample. We will only do this when the local COVID-19 restrictions in your area allow. To make the trial analysis as reliable as possible, we ask that even those who have stopped taking study treatment (for whatever reasons) continue to provide information on their health at six-monthly follow-up visits, and also provide a central blood sample, wherever possible. If you ran out of tablets because you were unable to come to a study clinic due to the COVID-19 pandemic and want to restart your tablets, please contact the local research team to arrange to be seen.


Some of you have had telephone follow-up during the global COVID-19 pandemic, but it is important we see you face-to-face to make clinical measurements, and in particular, collect the **vital blood samples needed for the trial's main result.**



Key Collaborating Centres: Duke Clinical Research Institute, North Carolina, US; University Clinic Würzburg, Germany; University of Tokyo Hospital and Tokai University, Japan; Klinisel, Kuala Lumpur, Malaysia; ANMCO Research Centre Florence, Italy; University of British Columbia, Vancouver, Canada; Jinling Hospital, Nanjing and Fuwai Hospital, Beijing, China.

Where do your blood and urine samples go?


At study visits, your blood and urine is taken and measured locally to help ensure it is safe for you to continue taking the study treatment. You also have provided vital samples for analysis at the study's Laboratory at the University of Oxford. These samples are frozen in your clinic, transported all the way to Oxford, and are processed by laboratory staff. The photographs show what happens to your samples. **Every participant and all samples are important.**




If you have any feedback, write or email to the following addresses:

**EMPA-KIDNEY
Central Coordinating
Office,
Clinical Trial
Service Unit and
Epidemiological
Studies Unit (CTSU),
Richard Doll Building,
University of Oxford,
Roosevelt Drive,
OXFORD,
OX3 7LF, UK**
cco.empakidney@ndph.ox.ac.uk

University of British
Columbia,
Vancouver,
Canada
488
Participants



CTSU
University of Oxford
UK
1133 Participants




University Clinic Würzburg
Germany
1269 Participants




Jinling Hospital,
Nanjing and Fuwai Hospital
Beijing, **China**
986 Participants



Duke Clinical Research Institute
North Carolina, **US**
1229 Participants



ANMCO
Research Centre
Florence, **Italy**
246 Participants



Klinsel, Kuala Lumpur
Malaysia
646 Participants



University of
Tokyo Hospital
and
Tokai University
Japan
612 Participants



6609 Participants have joined the EMPA-KIDNEY trial from **8** countries